Roth Capital Issues Positive Outlook for Cingulate Earnings

Cingulate Inc. (NASDAQ:CING) – Analysts at Roth Capital upped their Q1 2025 earnings per share estimates for shares of Cingulate in a research report issued on Monday, March 31st. Roth Capital analyst B. Pachaiyappan now expects that the company will earn ($0.96) per share for the quarter, up from their previous forecast of ($2.19). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.48) EPS.

A number of other brokerages have also weighed in on CING. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Cingulate in a report on Thursday, March 6th. Roth Mkm assumed coverage on Cingulate in a research note on Friday, January 10th. They issued a “buy” rating and a $12.00 price target on the stock.

Cingulate Stock Down 2.1 %

Shares of Cingulate stock opened at $4.16 on Wednesday. Cingulate has a 52-week low of $1.80 and a 52-week high of $20.83. The company has a market capitalization of $13.36 million, a P/E ratio of -0.28 and a beta of -0.83. The company has a 50 day moving average of $4.24 and a 200 day moving average of $4.43.

Institutional Investors Weigh In On Cingulate

A number of institutional investors have recently added to or reduced their stakes in CING. AlphaMark Advisors LLC boosted its holdings in Cingulate by 50,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after buying an additional 5,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Cingulate during the 3rd quarter worth approximately $106,000. Geode Capital Management LLC acquired a new stake in shares of Cingulate in the 4th quarter worth approximately $135,000. Finally, Commonwealth Equity Services LLC increased its stake in Cingulate by 281.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock valued at $212,000 after purchasing an additional 31,746 shares in the last quarter. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.